Compound class:
Synthetic organic
Comment: MI-503 inhibits the interaction between MLL oncoproteins (re-arranged lysine methyltransferase 2A; KMT2A; a.k.a. MLL1) and the tumour suppressor protein menin (MEN1, O00255), by binding directly to MLL binding site on menin [1]. MI-503 is active in vivo, exhibiting selective antiproliferative effects on cells harbouring MLL rearrangements. It represents a highly optimised molecular scaffold for clinical lead identification in the development of drugs for the treatment of aggressive MLL-rearranged leukemias.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
4-methyl-1-(1H-pyrazol-4-ylmethyl)-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]indole-2-carbonitrile |
Database Links ![]() |
|
GtoPdb PubChem SID | 336446912 |
PubChem CID | 91667931 |
RCSB PDB Ligand | 3XW |
Search Google for chemical match using the InChIKey | DETOMBLLEOZTMZ-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | DETOMBLLEOZTMZ |
UniChem Compound Search for chemical match using the InChIKey | DETOMBLLEOZTMZ-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | DETOMBLLEOZTMZ-UHFFFAOYSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
MI-503 (links to external site)
Cat. No. HY-16925 |